Prestige Consumer Healthcare (PBH) vs Supernus Pharmaceuticals (SUPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Supernus Pharmaceuticals (SUPN) has outperformed Prestige Consumer Healthcare (PBH) over the past year, losing 12.2% versus a loss of 24.4%. Over five years, SUPN leads with a +33.1% price change compared with -18.1% for PBH. Supernus Pharmaceuticals is the larger company by market cap ($2.50 billion vs $2.30 billion), about 1.1 times the size.
On valuation, Prestige Consumer Healthcare trades at a lower forward P/E (9.6x vs 9.6x for Supernus Pharmaceuticals). Prestige Consumer Healthcare converts more of its revenue into profit, with a net margin of 17.5% versus -5.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PBH | SUPN |
|---|---|---|
| Share price | $48.62 | $42.95 |
| Market cap | $2.30B | $2.50B |
| 1-day change | +1.57% | +1.91% |
| YTD return | -22.40% | -15.21% |
| 1-year return | -24.36% | -12.21% |
| 5-year return | -18.06% | +33.10% |
| P/E ratio (TTM) | 13.62 | — |
| Forward P/E | 9.57 | 9.63 |
| EPS (TTM) | $3.57 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.09B | $718.95M |
| Revenue growth (YoY) | -4.31% | +8.63% |
| Net income (latest FY) | $190.30M | $-38.55M |
| Gross margin | 54.71% | 89.63% |
| Operating margin | 28.42% | -8.66% |
| Net margin | 17.48% | -5.36% |
| 52-week high | $71.07 | $59.68 |
| 52-week low | $42.62 | $40.51 |
| Distance from 52-week high | -31.59% | -28.04% |
| Analyst consensus | buy | none |
| Avg. price target upside | +39.45% | +43.79% |
| Average volume | 547.31K | 756.95K |
| Shares outstanding | 47.37M | 58.22M |
| Employees | 890 | 778 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SUPN has outperformed PBH by 12.2 percentage points over the past year.
- Prestige Consumer Healthcare is more profitable, keeping 17.5 cents of every revenue dollar as net income versus -5.4 cents for Supernus Pharmaceuticals.
- Supernus Pharmaceuticals grew revenue faster in its latest fiscal year (+8.63% vs -4.31%).
About Prestige Consumer Healthcare
PBH stock →Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees
About Supernus Pharmaceuticals
SUPN stock →Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD.
Health Care · Biotechnology: Pharmaceutical Preparations · 778 employees
PBH vs SUPN FAQ
Which is bigger, Prestige Consumer Healthcare or Supernus Pharmaceuticals?
Supernus Pharmaceuticals (SUPN) is larger, with a market capitalization of $2.50B compared with $2.30B for Prestige Consumer Healthcare (PBH).
Which stock has performed better over the past year, PBH or SUPN?
SUPN returned -12.21% over the past 12 months, compared with -24.36% for PBH (price return, excluding dividends). Past performance does not predict future results.
Are Prestige Consumer Healthcare and Supernus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.